Haemonetics (NYSE:HAE) Stock Rating Cut to “Buy” at Wall Street Zen

Wall Street Zen lowered shares of Haemonetics (NYSE:HAE) from a strong-buy rating to a buy rating in a report published on Saturday,Wall Street Zen reports.

Several other equities analysts have also issued reports on the stock. BTIG Research boosted their price target on shares of Haemonetics from $130.00 to $142.00 and gave the company a “buy” rating in a report on Thursday. Mizuho set a $165.00 price objective on Haemonetics in a research note on Thursday. Barrington Research lifted their target price on Haemonetics from $140.00 to $145.00 and gave the stock an “outperform” rating in a report on Friday. JPMorgan Chase & Co. boosted their target price on Haemonetics from $62.00 to $86.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Finally, Citigroup boosted their target price on Haemonetics from $123.00 to $149.00 and gave the company a “buy” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $126.38.

Haemonetics Stock Down 3.4%

Shares of NYSE HAE opened at $119.87 on Friday. The stock has a market cap of $5.45 billion, a P/E ratio of 53.75, a P/E/G ratio of 2.40 and a beta of 0.63. The firm has a 50 day moving average price of $111.48 and a 200 day moving average price of $80.05. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.91 and a current ratio of 2.84. Haemonetics has a 52-week low of $51.00 and a 52-week high of $132.00.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 EPS for the quarter, beating the consensus estimate of $1.29 by $0.06. The firm had revenue of $357.76 million during the quarter, compared to the consensus estimate of $345.15 million. Haemonetics had a net margin of 7.52% and a return on equity of 27.42%. The business’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.27 earnings per share. Analysts expect that Haemonetics will post 5.32 EPS for the current year.

Hedge Funds Weigh In On Haemonetics

Several institutional investors and hedge funds have recently modified their holdings of HAE. Brighton Jones LLC bought a new stake in shares of Haemonetics during the 3rd quarter worth about $264,000. May Hill Capital LLC raised its holdings in Haemonetics by 12.1% in the 3rd quarter. May Hill Capital LLC now owns 25,093 shares of the medical instruments supplier’s stock valued at $2,642,000 after acquiring an additional 2,705 shares during the period. Vise Technologies Inc. bought a new position in Haemonetics in the 3rd quarter valued at about $613,000. VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in Haemonetics by 178.6% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 11,700 shares of the medical instruments supplier’s stock valued at $1,232,000 after acquiring an additional 7,500 shares during the period. Finally, VestGen Advisors LLC acquired a new stake in Haemonetics during the third quarter worth approximately $2,901,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Quarterly results beat expectations: Haemonetics earned $1.35 per share versus estimates of $1.29 and generated $357.8 million in revenue, above the $345.2 million consensus and up 9.4% year over year. Earnings and outlook report
• Positive Sentiment: Raised fiscal 2027 outlook: The company increased its full-year revenue and organic-growth outlook, forecasting organic growth of 6%–9%. Fiscal 2027 outlook
• Positive Sentiment: Analyst price targets rose: Citigroup raised its target to $149 and maintained a Buy rating; Barrington Research lifted its target to $145 with an Outperform rating; and BTIG raised its target to $142 with a Buy rating. Citigroup recommendations
• Neutral Sentiment: Growth comes with execution considerations: Haemonetics plans to scale the CSL Persona PLUS rollout through calendar 2027, and earnings-call coverage noted growth and margin tradeoffs. This may temper enthusiasm if rollout costs or margins disappoint. Earnings call highlights

About Haemonetics

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.